human chondrosarcoma cell lines sw1353  (ATCC)

Journal: Discover Oncology

Article Title: Mendelian randomization analysis of causal relationships between chondrosarcoma and angiogenesis related genes

doi: 10.1007/s12672-026-04621-0

Figure Lengend Snippet: RT-qPCR Validation of Key Genes in Chondrosarcoma Cell Lines. (A-D) Relative expression levels of LINC00984, TXNDC2, MPL28, and RP11-474N24.6 in SW1353, JJ012, and OUMS-27 chondrosarcoma cell lines compared to normal C28/I2 chondrocytes. Data represent mean ± SD from three independent experiments. *** P < 0.001, ** P < 0.01 vs. control group

Article Snippet: Human chondrosarcoma cell lines SW1353, JJ012, and OUMS-27, along with normal human chondrocyte cell line C28/I2 (control), were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C with 5% CO2.

Techniques: Quantitative RT-PCR, Biomarker Discovery, Expressing, Control

Journal: Bioresources and Bioprocessing

Article Title: Ulvan and Ulva oligosaccharides from Ulva sp. attenuate osteoarthritis in a high-fat diet and ligamentous meniscal injury-induced rat model

doi: 10.1186/s40643-026-01012-9

Figure Lengend Snippet: Effects of UE and UH on the production of IL-6, MMP-3, and Collagen 2α1 in MIA-induced SW1353 cells. Data are presented as mean ± SD ( n = 3). # indicates significant difference at p < 0.05; ## indicates significant difference at p < 0.01. Collagen 2α1, Collagen Type II Alpha 1; IL, interleukin; MIA, monosodium iodoacetate; MMP, matrix metalloproteinase; UE, Ulva extract; UH, Ulva hydrolysate

Article Snippet: The human chondrosarcoma cell line SW1353 was purchased from the Bioresource Collection and Research Center of the Food Industry Research and Development Institute and the American Type Culture Collection (ATCC).

Techniques:

Journal: Cells

Article Title: Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

doi: 10.3390/cells15050392

Figure Lengend Snippet: In vitro tube formation ability by chondrosarcoma cells. ( A ) Representative images of HUVEC (upper panels) or Sarc cells (lower panels) seeded onto GFR-Matrigel and allowed to form vascular tubules in vitro in the absence of serum (CTRL) or in the presence of FBS. Images acquired using an inverted phase-contrast microscope (Axiovert 200) and Axiovision 4.8 software (Zeiss). Scale bar, 100 μm or 50 μm in panels with higher magnification. Periodic acid—Schiff staining performed on HUVECs and Sarc cells (panels on the right) effectively shows that the newly formed tubes are rich in PAS-positive glycogen. ( B ) Representative images of SW1353 cell line and patient-derived ChS cells (ChS-1, ChS-2, and ChS-3), seeded onto GFR-Matrigel and allowed to form vascular-like tubules. Images acquired using an inverted phase-contrast microscope (Axiovert 200) and Axiovision 4.8 software (Zeiss). Scale bar, 500 μm.

Article Snippet: The SW1353 chondrosarcoma cell line, provided by ATCC, was cultured in Leibovitz’s L-15 Medium (Gibco) with the addition of 10% FBS, 100 μg/mL streptomycin and 100 IU/mL penicillin and maintained at 37 °C, 100% air, according to the manufacturer’s instructions.

Techniques: In Vitro, Microscopy, Software, Staining, Derivative Assay

Journal: Cells

Article Title: Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

doi: 10.3390/cells15050392

Figure Lengend Snippet: ChS cells do not express VEGFR-2, and VEGF-A does not trigger Sarc cell proliferation. ( A ) Cell lysates (40 µg/samples) from the SW1353 cell line, patient-derived ChS cells, stabilized Sarc cells and HUVECs were resolved on a 10% SDS-PAGE under reducing conditions and transferred onto a nitrocellulose membrane, followed by Western blot with anti-VEGFR-2 and anti-GAPDH as loading control. Chemiluminescent signals were detected and images captured using the eBright 1500 imaging system. ( B , C ) Time-dependent Sarc cell ( B ) and HUVEC ( C ) proliferation monitored using the xCELLigence RTCA technology. Briefly, 1 × 10 4 Sarc cells ( B ) or HUVECs ( C ), seeded in E-16-well plates in the absence (None, in red) or in the presence of 50 ng/mL VEGF-A (VEGF, in blue), were allowed to proliferate over 96 h. The histograms (right panels) report the slope analysis (time range 0–96 h). Data represent mean ± SD from quadruplicate experiments. Student’s t -test ns, not significant; *** p < 0.001.

Article Snippet: The SW1353 chondrosarcoma cell line, provided by ATCC, was cultured in Leibovitz’s L-15 Medium (Gibco) with the addition of 10% FBS, 100 μg/mL streptomycin and 100 IU/mL penicillin and maintained at 37 °C, 100% air, according to the manufacturer’s instructions.

Techniques: Derivative Assay, SDS Page, Membrane, Western Blot, Control, Imaging

Journal: Cells

Article Title: Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

doi: 10.3390/cells15050392

Figure Lengend Snippet: Flow cytometry analysis of vasculogenic-related markers on ChS cell surfaces. The expression levels of vasculogenic markers on SW1353, patient-derived ChS-1, ChS-2, ChS-3, stabilized Sarc ChS cells and HUVECs (with the last cell type used for comparison) were determined by flow cytometry using anti-CD34_PE-Cy7 (sky blue), anti-Podoplanin_ABflo 488 (red), anti-CD31_ABflo 647 (blue), anti-VE Cadherin_ABflo 488 (magenta), anti-EphA2-Alexa 488 (yellow) and anti-uPAR_APC (green). Unstained cells or omission of the primary antibody (when using unconjugated anti-EphA2) were used as negative controls (black lines).

Article Snippet: The SW1353 chondrosarcoma cell line, provided by ATCC, was cultured in Leibovitz’s L-15 Medium (Gibco) with the addition of 10% FBS, 100 μg/mL streptomycin and 100 IU/mL penicillin and maintained at 37 °C, 100% air, according to the manufacturer’s instructions.

Techniques: Flow Cytometry, Expressing, Derivative Assay, Comparison

Journal: Cells

Article Title: Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

doi: 10.3390/cells15050392

Figure Lengend Snippet: The inhibitor peptide RI-3 impairs the VM ability of ChS cells. ( A – C ) Representative images of VM by SW1353 ( A ) or patient-derived ChS-1 cells ( C ) suspended in serum free medium (Ctrl-) or 4% FBS medium and seeded onto GFR-Matrigel, in the absence of treatment (None) or in the presence of 10 nM RI-3 peptide or 500 μg/mL Bevacizumab (Beva), and allowed to form vascular-like tubules for 24 h. ( B – D ) The histograms report the quantitative analysis of VM formation performed by the Angiogenesis Analyzer tool of ImageJ software. Data represent mean ± SD from quadruplicate experiments performed at least three times. Student’s t -test ns, not significant, ** p < 0.01, *** p < 0.001.

Article Snippet: The SW1353 chondrosarcoma cell line, provided by ATCC, was cultured in Leibovitz’s L-15 Medium (Gibco) with the addition of 10% FBS, 100 μg/mL streptomycin and 100 IU/mL penicillin and maintained at 37 °C, 100% air, according to the manufacturer’s instructions.

Techniques: Derivative Assay, Software